WELLCOME SELL-OFF SANCTIONED

10 May 1992

The Wellcome Trust has received the sanction of the UK High Court to reduce its stake in the UK-based pharmaceutical concern, Wellcome, from 73.6% to 25%. The court said the Trust could sell up to 417 million shares.

The Trust is a medical charity and is planning to sell a large share of its holding in Wellcome in a sale expected to take place this summer. The sales should attract interest from overseas (Marketletter March 9). The Trust was first established by Sir Henry Wellcome.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight